COR CORPORA PORATE TE PRES PRESENT ENTATION TION August 9, - - PowerPoint PPT Presentation

cor corpora porate te
SMART_READER_LITE
LIVE PREVIEW

COR CORPORA PORATE TE PRES PRESENT ENTATION TION August 9, - - PowerPoint PPT Presentation

COR CORPORA PORATE TE PRES PRESENT ENTATION TION August 9, 2017 SAFE SAFE HARBOR HARBOR ST STATE TEME MENT NT This presentation and any statements made for and during any presentation or meeting contain forward-looking statements


slide-1
SLIDE 1

COR CORPORA PORATE TE PRES PRESENT ENTATION TION

August 9, 2017

slide-2
SLIDE 2

Corporate Presentation I August 9, 2017

SAFE SAFE HARBOR HARBOR ST STATE TEME MENT NT

This presentation and any statements made for and during any presentation or meeting contain forward-looking statements related to Synergy Pharmaceuticals Inc. under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These statements may be identified by the use of forward-looking words such as "anticipate," "planned," "believe," "forecast," "estimated," "expected," and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the development, launch, introduction and commercial potential of TRULANCE™; growth and opportunity, including peak sales and the potential demand for TRULANCE, as well as its potential impact on applicable markets; market size; substantial competition;

  • ur ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of

government or third party payer reimbursement; dependence upon third parties; our financial performance and results, including the risk that we are unable to manage our operating expenses or cash use for operations, or are unable to commercialize our products, within the guided ranges or

  • therwise as expected; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any

pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this presentation will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in our most recent periodic reports filed with the Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2016. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and we do not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances except as required by law. The information in this presentation is not targeted at the residents of any particular country or jurisdiction and is not intended for distribution to, or use by, any person in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

2

slide-3
SLIDE 3

Corporate Presentation I August 9, 2017

2017 IS A IS A TRANSFO TRANSFORM RMATI TIVE E YEAR YEAR FOR OR SYNER SYNERGY GY

January 19, 2017 FDA approves Trulance for the treatment of adults with CIC March 20, 2017 Synergy begins marketing Trulance in CIC April 12, 2017 Three new patents issued, expected to extend Trulance exclusivity until 2032 June 7, 2017 IBS-C sNDA accepted for FDA review; PDUFA date January 24, 2018

3

March 24, 2017 Submitted IBS-C sNDA for FDA review

slide-4
SLIDE 4

Corporate Presentation I August 9, 2017

  • Positive early launch signals – significant opportunity ahead
  • Expect to launch with IBS-C indication early next year
  • Control 100% worldwide rights
  • Strong patent portfolio with long life span
  • Commercial team and sales force with significant GI experience and several

product launches – 100% focused on Trulance

TR TRULAN ULANCE: CE: FOU FOUND NDATIO TION N TO O OUR OUR SUCCE SUCCESS SS

4

slide-5
SLIDE 5

TR TRULAN ULANCE CE LA LAUNC UNCH H UPD UPDATE TE

slide-6
SLIDE 6

Corporate Presentation I August 9, 2017

SYNER SYNERGY GY AND AND TR TRULANC ULANCE: E: WELL WELL POSITI POSITION ONED ED FOR SU FOR SUCCESS CCESS

6

RIGHT RIGHT

STRATEGY

RIGHT RIGHT

TEAM

RIGHT IGHT

MARKET

RIGHT RIGHT

PRODUCT

slide-7
SLIDE 7

Corporate Presentation I August 9, 2017

SYNER SYNERGY GY AND AND TR TRULANC ULANCE: E: WELL WELL POSITI POSITION ONED ED FOR SU FOR SUCCESS CCESS

7

RIG IGHT HT

MARKET

RI RIGHT

STRATEGY

RIG RIGHT

TEAM

RI RIGHT

PRODUCT

  • Large, Growing Market
  • Clear Unmet Needs
  • Significant Opportunity for Continued Branded Rx Growth
slide-8
SLIDE 8

Corporate Presentation I August 9, 2017

ESTI ESTIMA MATED TED 45 45 MI MILL LLION ION U.S. .S. ADU ADULTS TS SUFFE SUFFER R FR FROM OM CIC OR CIC OR IBS IBS-C C

10 20 30 40 50

Migraine GERD CIC/IBS-C

Estimated U.S. Prevalence (in millions)

~33 million U.S. adults suffer from CIC alone

Sources: Suares and Ford, Am J Gastroenterol 2011; 106:1582–159; GERD Prevalence : Sharma, Am J Gastroenterol 2008;103(11):2669-2680; Migraine Prevalence : Smitherman TA, Headache. 2013 Mar;53(3):427-36

8

slide-9
SLIDE 9

Corporate Presentation I August 9, 2017

NEW NEW ENT ENTRANTS RANTS ARE ARE GROWING GROWING THE THE MARKE MARKET, T, NOT NOT CANNIB CANNIBALIZIN LIZING G EXI EXIST STING ING PRODUCT PRODUCTS

11,729 12,606 12,878 13,412

1,288 1,345 1,476 1,488 1,422 2,112 2,691

13,578 15,373 16,465 17,591

5,000 10,000 15,000 20,000

2013 2014 2015 2016 TRxs in Thousands All Other Rx Amitiza Linzess

~ 4 MM

Last four years, TRx volume has grown by nearly 4 million or 30%

All Other Rx = Rx lactulose & Rx polyethylene glycol Source: QuintilesIMS, NPA

9

slide-10
SLIDE 10

Corporate Presentation I August 9, 2017

$182 $184 $171 $166 $326 $378 $436 $467 $382 $654 $959 $642 $945 $1,260 $0 $500 $1,000 $1,500 2013 2014 2015 2016 US $ in Millions All Other Rx Amitiza Linzess

VAL ALUE UE OF OF T THE HE PRES PRESCRIPT CRIPTION ION CON CONST STIP IPATIO TION N MARKET MARKET HAS HAS MORE MORE THAN THAN DOUBLED DOUBLED OVER VER THE THE PAST AST FOU FOUR R YEA YEARS RS + 148%

1,593 $133

All Other Rx = Rx lactulose & Rx polyethylene glycol Source: QuintilesIMS, NSP

10

slide-11
SLIDE 11

Corporate Presentation I August 9, 2017

ST STILL ILL AN AN UNT UNTAPP APPED ED US MARKE US MARKET OPP OPPOR ORTU TUNIT NITY

11

~ 45MM U.S. ADULTS WITH CIC / IBS-C

Branded Rx market serving

< 5% > 95%

currently not treated with branded Rx therapies

GROWTH DRIVERS

  • Increasing awareness of “gut health”
  • Significant investment to build market
  • HCP promotion will continue providing

appropriate information to prescribers regarding branded CIC/IBS-C Rx products

  • Disease awareness/education and direct to

consumer campaigns will continue to enable patients to ask about treatment options

  • Launch of Trulance

Source: QuintilesIMS, NPA - December 2016

slide-12
SLIDE 12

Corporate Presentation I August 9, 2017

ST STILL ILL CLEAR CLEAR UNME UNMET T NEE NEEDS DS IN IN THE THE MARKE MARKET

KEY KEY INS INSIGHT IGHTS

  • Bowel-Centered life
  • Still seeking solutions
  • Dissatisfied with OTCs
  • Seek normalcy

PATI TIENT ENTS

  • Challenging patients
  • Frustrated
  • Recycling
  • Any BM = Good BM

HCPs HCPs

Source: Company Data

12

slide-13
SLIDE 13

Corporate Presentation I August 9, 2017

SYNER SYNERGY GY AND AND TR TRULANC ULANCE: E: WELL WELL POSITI POSITION ONED ED FOR SU FOR SUCCESS CCESS

13

RIG IGHT HT

PRODUCT

  • Clinical Data
  • Market Research and Customer Insights
  • Label

RI RIGHT

STRATEGY

RIG RIGHT

TEAM

RI RIGHT

MARKET

slide-14
SLIDE 14

Corporate Presentation I August 9, 2017

TR TRULAN ULANCE CE PR PROVIDES VIDES A A NEW NEW TRE TREATM TMEN ENT T OPT OPTION ION FOR FOR MILLION MILLIONS S OF ADUL OF ADULTS TS WITH WITH CIC CIC

14

Pharmacology

  • Only product thought to replicate the pH-sensitive activity of uroguanylin

Efficacy

  • Evaluated in the two largest Phase 3 CIC trials to-date

Safety / Tolerability

  • Diarrhea was most common adverse event (5%)

Dosing

  • Once a day, any time of the day, with or without food

Note: Trulance Phase 3 CIC studies were conducted vs. placebo (and not an active comparator)

slide-15
SLIDE 15

Corporate Presentation I August 9, 2017

TR TRULAN ULANCE CE PR PROVIDES VIDES SIM SIMPLE PLE DOSING DOSING AND AND CONVENI CONVENIENT ENT PACKA CKAGIN ING G THA THAT T IS P IS PATIE TIENT NT PRE PREFERRE FERRED* D*

Convenient & Innovative Packaging

Simple Dosing & Administration Once a day Any time of day With or without food

*Source: Company Data

15

slide-16
SLIDE 16

Corporate Presentation I August 9, 2017

  • Launch Brand = Launch Mode
  • Key Launch Strategies and Activities

SYNER SYNERGY GY AND AND TR TRULANC ULANCE: E: WELL WELL POSITI POSITION ONED ED FOR SU FOR SUCCESS CCESS

RIG IGHT HT

STRATEGY

16

RIG RIGHT

TEAM

RI RIGHT

PRODUCT

RI RIGHT

MARKET

slide-17
SLIDE 17

Corporate Presentation I August 9, 2017

LESS LESS THAN THAN 20 20% OF % OF PRE PRESCR SCRIB IBERS ERS ARE ARE CURRE CURRENTL TLY Y WRIT WRITING ING 70 70% OF % OF THE THE TOTAL AL BRAND BRANDED ED PRE PRESCR SCRIPT PTIO IONS NS

Decile Rx Mean # of Doctors % of Doctors # of Prescriptions % of Prescriptions 10 460 753 0.5% 346,054 10.0% 9 245 1,411 0.9% 346,028 10.0% 8 163 2,120 1.3% 346,114 10.0% 7 113 3,057 1.9% 346,196 10.0% 6 78 4,440 2.7% 346,134 10.0% 5 54 6,448 4.0% 346,132 10.0% 4 36 9,484 5.9% 346,141 10.0% 3 24 14,549 9.0% 346,145 10.0% 2 14 25,109 15.5% 346,109 10.0% 1 4 94,563 58.4% 346,071 10.0% Total 161,934 100% 3,461,124 100% 4-10 27,713 17% 2,422,799 70% Branded Rx Combined

27,713 HCPs = 70% of Rx’s

  • ~ 45% primary care physicians
  • ~ 30% gastroenterologists
  • ~ 18% nurse practitioners or

physician assistants

Decile 3: 2 Rx’s per month Decile 2: ~ 1 Rx per month Decile 1: = 1 Rx every 3 months

Source: QuintilesIMS Xponent - March 2017; excluding non-called on specialties (peds, pain, hem/onc)

17

slide-18
SLIDE 18

Corporate Presentation I August 9, 2017

Key Points:

  • The ~27K prescribers are within 15K

group practices/offices

  • Reaching the 27K prescribers with an

experienced sales force and surround sound of promotional efforts

TAR ARGET GETED ED SALE SALES ST S STRA RATE TEGY Y FOCU FOCUSE SED D ON ON A A CON CONCENTR CENTRATED ED PRES PRESCRI CRIBER ER BASE ASE

1.0MM TRx (30%)

2.4MM TRx (~70%)

Branded Rx Market

27,713 Prescribers

134,221 Prescribers

Source: QuintilesIMS Xponent - March 2017; excluding non-called on specialties (peds, pain, hem/onc)

18

slide-19
SLIDE 19

Corporate Presentation I August 9, 2017

KEY KEY CUST CUSTOME OMERS S AND AND LA LAUNCH UNCH ST STRA RATE TEGIE GIES

Lau Launc nch h Str Strate tegies gies

Drive Awareness of Trulance and Stimulate Trial and Adoption

HCPs CPs PAYERS YERS PATIE TIENTS TS

Ensure Access Activate and Support the Rx Ready Patient

19

slide-20
SLIDE 20

Corporate Presentation I August 9, 2017

HCPs HCPs

  • Drive Awareness of

Trulance and Stimulate Trial / Adoption

  • Activate and Support the

Rx Ready Patient

  • Ensure Access

✓ Sales force of ~ 250 educating ~ 27,000 prescribers ✓ Over 360,000 sample packs distributed to field to date ✓ ~ 400 peer-to-peer speaker programs, > 5,200 attendees ✓ Launched comprehensive HCP media plan ✓ DDW 2017 – significant promotional presence; 6 abstracts (two posters of distinction, one oral presentation)

KEY KEY LA LAUNCH UNCH ST STRA RATE TEGIES IES AND AND ACTI CTIVI VITIE TIES

Source: Company Data

20

slide-21
SLIDE 21

Corporate Presentation I August 9, 2017

✓ Trulance Campaign:

▬ Point of Care Promotion: ~ 20,000 offices ▬ Web Sponsorships/Display Ads: > 101M impressions ▬ Search Engine Marketing: > 312,000 clicks ▬ Trulance.com visits: > 500,000 for consumer site

✓ Confront Constipation Campaign:

▬ Disease awareness initiative ▬ 33 original media placements ▬ > 300M media impressions ▬ ~ 92,000 Emoji App downloads

KEY KEY LA LAUNCH UNCH ST STRA RATE TEGIES IES AND AND ACTI CTIVI VITIE TIES

  • Drive Awareness of

Trulance and Stimulate Trial / Adoption

  • Activate and Support the

Rx Ready Patient

  • Ensure Access

PATIE TIENTS TS

Source: Company Data

21

slide-22
SLIDE 22

Corporate Presentation I August 9, 2017

✓ Removing barriers and gaining commercial open access ✓ > 61% of patients with commercial insurance have unrestricted access ✓ Trulance “Savings-to-Go” program ensures copay of $25/Rx for > 95% of patients with commercial insurance ✓ Trulance Access Support Services Program ✓ Medicare Part D and Medicaid Discussions Ongoing

KEY KEY LA LAUNCH UNCH ST STRA RATE TEGIES IES AND AND ACTI CTIVI VITIE TIES

PAYERS YERS

  • Drive Awareness of

Trulance and Stimulate Trial / Adoption

  • Activate and Support the

Rx Ready Patient

  • Ensure Access

Source: Company Data

22

slide-23
SLIDE 23

Corporate Presentation I August 9, 2017

SYNER SYNERGY GY AND AND TR TRULANC ULANCE: E: WELL WELL POSITI POSITION ONED ED FOR SU FOR SUCCESS CCESS

  • Highly experienced team
  • Significant launch experience
  • Significant GI and PCP experience
  • From peer GI, specialty, and PCP companies

RIG IGHT HT

TEAM

23

RI RIGHT

STRATEGY

RI RIGHT

PRODUCT

RI RIGHT

MARKET

slide-24
SLIDE 24

Corporate Presentation I August 9, 2017

SYNE SYNERGY GY HYBRID HYBRID SALE SALES MODE S MODEL L

Hired our own Sales Leaders

  • Synergy Area Business Directors average ~16 years
  • f pharma experience and ~ 10 years in GI
  • Synergy Regional Business Directors average over 11

years of management experience with over 10 years in relevant GI fields

  • Synergy Regional GI Account Specialists / Field

Trainers average 13 years of pharmaceutical experience and 8.5 years of GI experience

Flexible & Operationally Efficient CSO Approach

  • Strong partnership with Publicis Touchpoint in

recruiting and hiring all of the GI Account Specialists

  • Synergy leads training, territory management, sales

direction / tactical activities

  • Average 11.5 years of pharmaceutical experience and

nearly 6 years in GI, with over 93% coming from peer GI / Specialty / PCP companies

Synergy Sales Leaders GI Account Specialists

FULLY DEDICATED TO TRULANCE

24

slide-25
SLIDE 25

KEY KEY LA LAUNCH UNCH PERFOR PERFORMA MANC NCE E METRICS METRICS

slide-26
SLIDE 26

Corporate Presentation I August 9, 2017

TR TRULANC ULANCE T E TOTAL M AL MONTHL ONTHLY PRESCRIPT Y PRESCRIPTION ION VOL OLUM UME E HAS HAS INCREASED O INCREASED OVER VER 182% ON A 182% ON AVERA VERAGE MONTH GE MONTH-OVER VER-MO MONTH NTH

Source: QuintilesIMS

26 394 1847 4162 6272

1,000 2,000 3,000 4,000 5,000 6,000 7,000 Mar-17 Apr-17 May-17 Jun-17

TRx Volume

Trulance Monthly Total Prescriptions

394 2241 6403 12675

2,000 4,000 6,000 8,000 10,000 12,000 14,000 Mar-17 Apr-17 May-17 Jun-17

TRx Volume

Trulance Cumulative Monthly Total Prescriptions

slide-27
SLIDE 27

Corporate Presentation I August 9, 2017

148 392 674 1096 1585 2213 2943 3799 4751 5866 6868 8120 9447 11023 12647 13995 15749 17491 19327

5,000 10,000 15,000 20,000 25,000 3/24/17 3/31/17 4/7/17 4/14/17 4/21/17 4/28/17 5/5/17 5/12/17 5/19/17 5/26/17 6/2/17 6/9/17 6/16/17 6/23/17 6/30/17 7/7/17 7/14/17 7/21/17 7/28/17

TRx Volume

Trulance Cumulative Weekly TRx Volume

TR TRUL ULANCE ANCE TOTAL AL WEEKL WEEKLY Y PRES PRESCRI CRIPT PTION ON VOL OLUME UME SHO SHOWING WING ST STRONG ONG CONSIS CONSISTE TENT NT GR GROWTH WTH

Holiday Week Holiday Week

124 244 282 422 489 628 730 856 952 1115 1002 1252 1327 1576 1624 1348 1754 1742 1836

200 400 600 800 1,000 1,200 1,400 1,600 1,800 2,000 3/24/17 3/31/17 4/7/17 4/14/17 4/21/17 4/28/17 5/5/17 5/12/17 5/19/17 5/26/17 6/2/17 6/9/17 6/16/17 6/23/17 6/30/17 7/7/17 7/14/17 7/21/17 7/28/17

TRx Volume

Trulance Weekly TRx Volume

Source: QuintilesIMS

27

slide-28
SLIDE 28

Corporate Presentation I August 9, 2017

TR TRULAN ULANCE CE NEW NEW-TO TO-BR BRAND ND MARKE MARKET T SHARE SHARE AT T 12 12% % AMONG AMONG GAST GASTROENT OENTER EROLOGISTS OGISTS

Source: QuintilesIMS

31.8% 22.5% 66.9% 65.4% 12.7% 12.0% 0% 10% 20% 30% 40% 50% 60% 70% 80% Jan-16 Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Prescription Market Share

NBRx Market Share Among Gastroenterologists

Amitiza Brand Linzess Brand Linzess 72mcg Trulance 3mg

LAUNCH

28

slide-29
SLIDE 29

Corporate Presentation I August 9, 2017

TR TRULAN ULANCE CE PRE PRESCR SCRIB IBERS ERS HA HAVE VE INCREASED INCREASED AN AN AVER VERAGE GE OF OF 14 140% MONT 0% MONTH-OVER ER-MONT ONTH H SINCE SINCE LA LAUNCH UNCH

257 1,145 2,427 3,768 1,000 2,000 3,000 4,000 5,000 March April May June Cumulative Trulance Prescribers

Source: QI XPT, launch through w/e 6/30/17

29

slide-30
SLIDE 30

Corporate Presentation I August 9, 2017

TR TRULAN ULANCE CE SOUR SOURCE CE OF B OF BUSINE USINESS SS (BRAN (BRANDED ED MARKE MARKET)

44% Rx convert 51% New therapy starts

5% Add On

Trulance NRx Breakdown

  • 51% of Trulance NRx were new branded

Rx therapy starts

  • 45% of Trulance patients have converted

from other Rx treatments

  • Majority coming from Linzess

30

Source: Weeks ending 3/17 – 6/30, QIMS XPD

slide-31
SLIDE 31

Corporate Presentation I August 9, 2017

  • Positive early launch signals
  • Early prescriber and patient experience appears promising
  • Continue to execute on our launch plan
  • Opportunity to “broaden the base” and build off of successful Trulance launch

▬ DTC development ▬ Prepare for IBS-C launch

OPT OPTIMIZ IMIZING ING THE THE VAL ALUE UE OF TR OF TRULAN ULANCE CE

31